KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Khiron Life Sciences Corp. has launched Latin America's first internationally accredited medical cannabis diploma program in partnership with TecSalud School of Medicine in Mexico, starting February 20, 2021. This six-week program aims to equip Latin American physicians with essential knowledge for the safe prescription of medicinal cannabis, marking a significant advancement in medical education in the region. Following Mexico's recent legislation on medical cannabis, Khiron plans to expand its Zerenia clinics, enhancing its presence in the burgeoning market.

Khiron Life Sciences Corp. announced plans to launch two additional small-format Zerenia™ clinics in major Colombian cities in early March 2021. This expansion follows the successful opening of their first clinic in Medellin in December 2020. With these new clinics, Khiron will operate six clinics nationwide, aiming to increase access to medical cannabis for approximately 6 million potential patients. The company reports strong patient demand, with eight out of ten patients receiving paid prescriptions in Medellin, highlighting the effectiveness of their direct-to-patient sales model.

Khiron Life Sciences Corp. (KHRNF) announced the award of restricted share units (RSUs) to new and existing directors and an officer. On February 8, 2021, the board approved the grants as part of its amended RSU plan. A total of 888,298 shares were allocated, with specific vesting schedules: 425,532 shares to Director Juan Carlos Echeverry, 212,766 to Director Deborah Rosati, and 250,000 to CFO Joel Friedman. The company is a leader in medical cannabis in Latin America and is expanding operations in Europe, aiming for sales in Germany and Brazil in early 2021.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) announced a live webcast on February 17, 2021, at 11:00am ET to discuss recent results and 2021 outlook. CEO Alvaro Torres and management will also engage in a 1x1 Virtual Roadshow on February 9-10 and participate in the Benzinga Cannabis Capital Conference on February 25-26. Highlights include a 50% compound monthly growth rate in medical cannabis prescriptions and the opening of a new clinic in Medellin, Colombia. The company continues to expand its presence in both Latin America and Europe.

Khiron Life Sciences Corp. (TSXV:KHRN)(OTCQX:KHRNF) will present at the virtual Fall Investor Summit from November 16-18, 2020. This event features 75 companies and attracts over 300 investors. Khiron is a leading cannabis company in Colombia, licensed for cultivation, production, and distribution of medical cannabis, with operations extending to Europe and North America. The company emphasizes patient-oriented approaches and holds a significant market position with products like its CBD skincare brand, Kuida™, available in multiple regions.

Khiron Life Sciences Corp. announced the appointment of Joel Friedman as CFO effective October 16, 2020, following the resignation of Wendy Kaufman, who held the position since July 2019. Friedman joined Khiron in December 2019 as Director of Finance and Treasury and is a Chartered Professional Accountant with over 10 years of experience, including roles at CannTrust Inc. and Primero Mining Corp. This leadership change is expected to support Khiron's growth in Latin America and internationally.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) announced that CEO Alvaro Torres will present at the Benzinga Virtual Cannabis Capital Conference on October 15, 2020. The conference aims to connect investors and cannabis entrepreneurs. Notably, Khiron has seen a dramatic 450% increase in medical cannabis prescriptions in Q3 2020 compared to Q2. The company also achieved over 3,500 prescriptions filled and surpassed 9,000 monthly patient consultations in September. Khiron is expanding its presence in Latin America and Europe, focusing on medical cannabis and consumer-packaged goods.

Khiron Life Sciences Corp. (KHRNF) reported significant growth in its medical cannabis operations, highlighting a 450% increase in prescriptions filled in Q3 2020, totaling over 3,500 prescriptions. The company exceeded 9,000 monthly patient consultations in September, returning to pre-pandemic levels. It was recognized as a National Strategic Project in Colombia, facilitating new product registrations. Khiron also began sales in Peru and partnered with clinics across Colombia. Additionally, it serves patients in the UK's Project Twenty21, enhancing its market reach.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) announced its participation in the 2020 Virtual US Cannabis Symposium on September 30, 2020. Company CEO Alvaro Torres and Chairman Chris Naprawa will present, discussing recent achievements such as filling over 3,000 medical cannabis prescriptions in Colombia and becoming the first to sell medical cannabis in Peru. The event is investor-focused, featuring one-on-one meetings. The recording will be available afterward for those who cannot attend.